A tighter archive for life-science signals.
Search once, then narrow by source or topic.
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Charles River to close cell therapy CDMO site, lay off 20 staffers
Charles River to close cell therapy CDMO site, lay off 20 staffers
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
BMS pens $850M solid tumor pact with T-cell engager biotech Janux
BMS pens $850M solid tumor pact with T-cell engager biotech Janux
Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat
Orca rides $250M funding wave toward cancer cell therapy launch
Orca rides $250M funding wave toward cancer cell therapy launch
Soley secures $200M series C to push AML cell stress drug into clinic
Soley secures $200M series C to push AML cell stress drug into clinic
Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease
Cellular energy booster restores cognition in mice with advanced Alzheimer’s disease
Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data
Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data By Nick Paul Taylor Dec 23, 2025 9:00am Parkinson's disease Parkinson's drug mesenchyma...
Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025
ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma
ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma
Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy
Capricor's phase 3 win sets up 2nd approval attempt for Duchenne cell therapy
Janux T-cell engager data sink stock, but analysts still see best-in-class potential
BIOTECH Janux T-cell engager data sink stock, but analysts still see best-in-class potential By Gabrielle Masson Dec 2, 2025 11:14am Janux Therapeutics T-cell engagers...
Imvax takes brain cancer cell therapy to FDA, betting survival hit will overshadow primary miss
Brought to you by: BIOTECH Imvax takes brain cancer cell therapy to FDA, betting survival hit will overshadow primary miss By Nick Paul Taylor Dec 2, 2025 8:00am Imvax...
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page